JCM | Free Full-Text | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis | HTML
Drug evaluation review: dupilumab in atopic dermatitis | Immunotherapy
Primary (A) and secondary (B) end points in phase III trials of... | Download Scientific Diagram
Efficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial - The Journal of Allergy and Clinical Immunology: In Practice
A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis,Allergy - X-MOL
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) - Journal
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease | Nature Reviews Drug Discovery
Drug evaluation review: dupilumab in atopic dermatitis. | Semantic Scholar
Figure 1 from Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. | Semantic Scholar
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis | NEJM
Research Developments in Atopic Dermatitis • A podcast on Anchor
Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis - The Journal of Allergy and Clinical Immunology: In Practice
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial - The Lancet
Dupixent | Eczema | Skin Centre | Skin Clinic |LM SKINCENTRE
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial - Journal of the American
Dupixent (dupilumab) for the Treatment of Atopic Dermatitis
